- Joined
- Oct 2, 2005
- Messages
- 12,024
- Reaction score
- 9,705
Thank you, not sure if the compliment is always warranted, but thanks anyway.
Here are my thoughts on oncology -- and I have no crystal ball -- but many of the treatments that we provide are for naught, many others are in pursuit of minimal gains, etc -- all of which is done at a measurable expense. Given that we live in a world with finite resources (including those monies available for seizure from the working private citizenry) and the fact that we have now relinquished the means of determination for the allocation of these finite resources to the government, the masses will have abide by the rules that they set in place. This will mean an application of "uniform standards" -- such as "quality adjusted life years", cost efficacy, and comparative effectiveness. The architects of our proposed system have gone on record praising Britain's NHS -- and we should all know the practice of oncology varies significantly between our two systems.
Even if they do not disallow many treatments, they will render them financially untenable for the private practice to provide. If you remove any possible profit potential via the price fixing mechanism, you have a de facto abolition of services without the political fallout. These services will then be relegated to treatment centers who enjoy some form of subsidization -- whether this is direct subsidization as is the case with university settings or via an indirect subsidization through the confiscation and reallocation of funds from more profitable ventures (think large MSC).
Another likely scenario would be the relegation of "unproven" or "treatments with questionable benefit" to nothing other than clinical trial status. This has been the push for some time by the academic types already -- a way of creating a special, privileged status for them at the expense of those in the community at large. It would be a great way to guarantee and funnel any and all remaining pharmaceutical monies into the hands of academia, would it not? Not that any of our esteemed colleagues would even so much as entertain such a thought...
Naturally, barring further state intervention and regulation, a secondary insurance market would evolve -- leading to a two tier healthcare system (which is what we were trying to avoid in the first place, right?).
Here are my thoughts on oncology -- and I have no crystal ball -- but many of the treatments that we provide are for naught, many others are in pursuit of minimal gains, etc -- all of which is done at a measurable expense. Given that we live in a world with finite resources (including those monies available for seizure from the working private citizenry) and the fact that we have now relinquished the means of determination for the allocation of these finite resources to the government, the masses will have abide by the rules that they set in place. This will mean an application of "uniform standards" -- such as "quality adjusted life years", cost efficacy, and comparative effectiveness. The architects of our proposed system have gone on record praising Britain's NHS -- and we should all know the practice of oncology varies significantly between our two systems.
Even if they do not disallow many treatments, they will render them financially untenable for the private practice to provide. If you remove any possible profit potential via the price fixing mechanism, you have a de facto abolition of services without the political fallout. These services will then be relegated to treatment centers who enjoy some form of subsidization -- whether this is direct subsidization as is the case with university settings or via an indirect subsidization through the confiscation and reallocation of funds from more profitable ventures (think large MSC).
Another likely scenario would be the relegation of "unproven" or "treatments with questionable benefit" to nothing other than clinical trial status. This has been the push for some time by the academic types already -- a way of creating a special, privileged status for them at the expense of those in the community at large. It would be a great way to guarantee and funnel any and all remaining pharmaceutical monies into the hands of academia, would it not? Not that any of our esteemed colleagues would even so much as entertain such a thought...
Naturally, barring further state intervention and regulation, a secondary insurance market would evolve -- leading to a two tier healthcare system (which is what we were trying to avoid in the first place, right?).